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Abstract 
 
Purpose: Preoperative embolization of radiographically suspected meningiomas is often 
performed to facilitate subsequent tumor resection. Its effects on the subsequent disease course of 
meningioma patients have not been studied in detail and randomized trials are lacking. The 
purpose of this study was to explore associations of preoperative meningioma embolization with 
postoperative outcome. 
Patients and Methods: Patients undergoing resection of an intracranial meningioma at the 
University Hospital Zurich 2000-2013 (N=741) were reviewed for the inclusion of pre-operative 
embolization in the management strategy. Annotations included demographics, radiographic, 
surgical, histological and hematological parameters, cardiovascular risk factors, pre- and 
postoperative neurological function and gene methylation-based classification. Binary regression 
and Cox proportional hazards models were applied to determine factors associated with outcome. 
Results: Pre-operative embolization was performed in 337 patients (42%). Cardiovascular events 
after surgery comprised mostly deep vein thrombosis (N=39) and pulmonary embolisms (N=64). 
On multivariate analyses of post-operative cardiovascular adverse events controlling for 
established risk factors, there were associations with embolization (OR 2.38, 95% CI 1.37-4.00), 
and with female gender (OR 2.18, 95% CI 1.17-4.08). Recurrence-free survival (RFS) of 
embolized patients was less favorable among patients with WHO grade II or grade III 
meningiomas (median RFS: 4.3 versus 7.0 years, P = .029) or in patients with intermediate or 
malignant gene methylation subtype meningiomas (median RFS: 2.0 versus 8.2 years, P = .005). 
Conclusion: Pre-operative meningioma embolization may cause adverse outcomes. Randomized 
trials to determine benefit-risk ratios are warranted to clarify the role of pre-operative 
embolization for the treatment of meningioma patients. 
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Introduction 
 
Meningiomas are the most common primary intracranial tumors in adults [1]. The World Health 
Organization (WHO) classification of tumors of the central nervous system assigns grades I-III 
based on histological criteria [2]. WHO grade I meningiomas are histologically benign and 
commonly treated with surgery alone, whereas WHO grade II and III meningiomas are 
characterized by microscopic signs of atypia and malignancy, recur frequently and are therefore 
often treated with post-operative radiotherapy [3,4,2]. 
Pre-operative tumor embolization utilizing microparticles is often performed to reduce blood loss 
during surgery and facilitate resection. Since prospective efficacy studies are lacking, controversy 
exists as to whether the risk of an additional procedure is justified [5,6]. Skepticism also arises 
regarding the frequent observation of cellular atypia and mitotic activity in peri-necrotic areas 
after embolization, which may mislead neuropathologists to overestimate tumor grade and 
subsequently provoke unnecessary adjuvant treatment [7,8]. 
Meningioma surgery is associated with moderate or severe morbidity in a substantial fraction of 
patients [9-12]. The risk of post-operative thrombosis and pulmonary embolism after 
meningioma resection exceeds that of other brain tumors [13,14,11,12]. Underlying causes that 
have been identified include duration of surgery, older age, comorbidities and surgical 
complications [12,11], but a potential role of pre-operative tumor embolization has not been 
studied in detail.  
Here we report the post-operative outcomes in a cohort of 741 consecutive meningioma patients 
according to whether or not they underwent pre-operative embolization. Outcomes were assessed 
in multivariate models that control for established prognostic factors.   
 
 
Patients and Methods 
  
Subject selection and study design 
 
Supplementary Figure 1 details the primary analysis population. A total of 779 consecutive 
patients that underwent neurosurgery for intracranial meningioma at the University Hospital 
Zurich between 2000 and 2013 were identified by an automated search of the electronic chart 
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system [9] and classified based on whether pre-surgical tumor embolization was performed 
within 1 month before surgery (group A), or not (group B). Thirty-eight patients were excluded 
from further analysis because of a time from embolization of more than 1 month before surgery 
(N=9), embolization after surgery (N=3), or a follow-up time of < 3 months after surgery in the 
absence of death (N=26).  
 
 
Gene methylation classification 
 
For methylation analysis, Illumina 450k Human BeadChip (Illumina, San Diego, CA) arrays 
were employed. Samples were assessed within the discovery cohort of the pivotal study defining 
methylation subgroups [15]. 
 
 
Pre-operative meningioma embolization 
 
Tumor embolization was performed under general anesthesia utilizing a 5F diagnostic catheter 
(Cook Medical, Bloomington, IN) for access through the right femoral artery by a modified 
Seldinger technique. Six-vessel angiography was performed prior to the introduction of a 
microcatheter for superselective angiographic analysis of the blood supply of the meningioma, 
followed by polyvinyl alcohol particle (PVA)-based embolization with microparticles measuring 
45 to 150 μm in diameter (Embozene® Microspheres; Celonova, San Antonio, TX). PVA 
injection was ceased when stagnation of blood flow in the terminal segment of respective arteries 
was achieved and all accessible feeder arteries were embolized. Tumor devascularization was 
confirmed on magnetic resonance imaging (MRI, Figure 1A) or computed tomography (CT) 
within 48 hours following the endovascular intervention. Enhanced mitotic activity in 
embolization-induced peri-necrotic tumor portions was not referenced for histopathological 
grading (Figure 1B). 
 
 
Variables 
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Clinical data were obtained by review of medical reports. Imaging data were reevaluated with a 
focus on maximal tumor diameter, hemorrhage and absence or presence of edema. Gross total 
resection (GTR) was defined as the absence of contrast enhancement on post-operative computed 
tomography (CT) or MRI scans. For safety analyses of the embolization procedure, events were 
considered related until surgery or for a maximum of 3 months. Adverse neurological outcome 
was defined as post-operative new onset of neurological symptoms, or as a worsening of 
neurological symptoms that persisted at least 3 months after surgery. Adverse cardiovascular 
outcome was defined as any of the following events within 3 months after surgery: pulmonary 
embolism, deep vein thrombosis, sinus vein thrombosis, ischemic stroke, myocardial infarction, 
and cardiovascular death or sudden death of unexplained cause. Time to recurrence was defined 
as the time to re-intervention, including re-resection, radiotherapy or systemic therapies, or death 
from meningioma progression. Post-operative radiotherapy of residual tumor was not classified 
as recurrence. 
 
 
Statistical methods 
 
The Chi Square test was performed for analyses of nominal and ordinal variables and the Mann-
Whitney-U test was performed for continuous variables. Binary logistic regression was 
performed for multivariate testing of factors associated with neurological outcome or 
cardiovascular complications of meningioma surgery and Cox proportional hazards models were 
applied to determine factors associated with recurrence-free survival.  
 
 
Results 
 
Study population 
 
The study population of 779 patients with histologically confirmed intracranial meningioma was 
previously characterized in the context of post-operative epilepsy risk [9]. Here, only patients 
with a minimum post-operative follow-up time of at least 3 months were included in analyses of 
neurological and cardiovascular outcome (N=741). This population included 337 patients 
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(42.3%) who underwent pre-operative tumor embolization (group A) and 404 patients (57.7%) 
who did not (group B) (Supplementary Figure 1). The median time to surgery was 2 days and the 
vast majority of embolized patients underwent embolization within one week prior to surgery 
(N=308, 91.4%, Supplementary Figure 2A). During a median follow-up time of 69 months (95% 
confidence interval [CI] 64-75), 167 patients (22.5%) experienced progressive or recurrent 
disease and 124 patients (16.7%) died.  
 
 
Clinical characteristics of patients with versus without pre-operative tumor embolization 
 
The clinical characteristics of patients in group A versus group B are summarized in Table 1. 
Age, gender, tumor location and presence of multiple meningiomas were balanced between both 
groups. Group A contained more WHO grade II or grade III versus grade I tumors, and of the 9 
histological WHO grade I variants, only psammomatous meningiomas were less frequent in 
group A versus group B (1.0% versus 3.4%, P = .042) (Supplementary Table 1). On imaging 
scans obtained prior to surgery, meningiomas in group A were larger and more frequently 
accompanied by peritumoral edema. Within group A, peritumoral edema was detected less 
frequently after versus before embolization. More detailed analyses of imaging scans in group A 
versus group B revealed similar rates for hyperostosis, intraosseous growth, extracranial growth 
or infiltration of venous sinuses in both groups. Yet, group A versus group B was associated with 
lower rates of calcification (22.3% versus 32.2%, P = .003) and of radiographic gross total 
resection (69.1% versus 80.3%, P = .001), and with higher rates of post-operative brain edema 
(55.0% versus 34.8%, P = .006) and intraaxial growth (9.3% versus 5.5%, P = .052) 
(Supplementary Table 2). Furthermore, Simpson grade 1 resection was achieved at lower rates in 
embolized patients, the median operation time was 1 h longer compared to the no embolization 
group, and embolization was linked to a higher rate of recurrent or progressive tumor growth 
during follow-up (Table 1), indicating higher surgical complexity of patients selected for 
preoperative embolization, e.g., due to a smaller fraction of patients with convexity meningiomas 
and larger tumor size in the embolization group. 
 
 
Complications from meningioma embolization 
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Any patients that underwent embolization for a radiographically suspected intracranial 
meningioma were included in safety analyses of the embolization procedure, regardless of 
whether surgery was done subsequently (N=358). Acute potentially live threatening or disabling 
complications from embolization occurred in 5 patients (1.4%), including stroke (N=3), 
intratumoral hemorrhage (N=1) and serial generalized epileptic seizures (N=1). Furthermore, two 
patients suffered mild transient neurological symptoms with gradual onset within 24 hours from 
embolization and good response to anti-edematous therapy, consisting of hemianopia and 
aphasia, respectively. One patient with Marfan syndrome suffered an aortic dissection 2 months 
after the embolization. There was no fatal complication. 
 
 
Neurological outcome after meningioma resection by embolization status 
 
Adverse neurological events within 3 months after surgery were more frequent in group A versus 
group B (57.0% verus 44.8%, P = .001). Supplementary Table 3 summarize the most common 
post-operative neurological events by study group. Rates of trigeminal neuralgia, sensorimotor 
deficits, visual deficits, early symptomatic seizures, neurocognitive deficits, central nervous 
system (CNS) infections and recraniotomy were similar in both groups, but cranial nerve palsy, 
hydrocephalus and intracranial hemorrhage as well as post-operative new onset epilepsy were 
more frequent in group A. Patients with pre-operative epilepsy were balanced between group A 
versus group B  (29.2% versus 35.0%, P = .091); however, a smaller fraction of patients with pre-
operative epilepsy became seizure free after surgery in group A versus group B (51.7% versus 
64.4%, P = .048). We have also analyzed residuals of adverse neurological events 1 year post-
operatively. Among 686 patients with a follow-up of at least 1 year, 316 (46.1%) were in group A 
and 370 (53.9%) in group B. In group A versus group B, 69 (21.8%) versus 67 (18.1%) patients 
had residuals from adverse neurological events associated with surgery (P = .22). 
 
 
Adverse cardiovascular events after meningioma resection by embolization status 
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Cardiovascular risk factors were balanced between both groups, including the number of risk 
factors (P = .84) and pre-operative cardiovascular events (P = .98, Table 2). Adverse 
cardiovascular events after surgery were more frequent in group A versus group B (17.5% versus 
8.2%, P < .001). Ischemic stroke, myocardial infarction and sinus vein thrombosis occurred at 
similar rates in both groups, but patients in group A suffered more deep vein thromboses and 
pulmonary embolisms, and group A was associated with a higher rate of death (Supplementary 
Table 3). Post-operative hematological parameters did not differ in group A versus group B, 
except for slightly lower median values for platelet counts (P = .002) and hematocrit (P < .001) 
(Supplementary Table 4).  
 
 
Multivariate and subgroup analyses 
 
We applied a binary logistic regression model controlling for demographics, WHO grade and 
imaging characteristics to test whether pre-operative tumor embolization is a predictor of 
cardiovascular outcome (Table 3). Univariate analyses of the association of variables included in 
this model are summarized in Supplementary Table 5. An association with higher cardiovascular 
risk was identified for group A (odds ratio [OR] 2.38, 95% CI 1.37-4.00, P = .002) and female 
gender (OR 2.18, 95% CI 1.17-4.08, P = .014). No association was identified for age, WHO 
grade, tumor size, presence of multiple meningiomas, radiographic extent of resection or 
cardiovascular risk factors. Factors that were tested as additional single variables in this model 
are summarized in Supplementary Table 6: Tumor location at the skull base (OR 2.33, 95% CI 
1.40-3.86, P = .001) and adverse neurological outcome (OR 1.75, 95% CI 1.05-2.86, P = .032) 
were associated with inferior cardiovascular outcome. In reverse, parasagittal tumor location (OR 
0.44, 95% CI 0.20-0.98, P = .045) and thrombocyte levels of 220/nl or higher on post-operative 
blood cell counts (OR 0.55, 95% CI 0.29-1.05, P = .069) correlated with lower cardiovascular 
risk. No association was identified for the presence or absence of pre-operative neurological 
deficits (P = .43), pre-operative brain edema (P = .93), post-operative brain edema (P = .64), 
duration of surgery (P = .31) tumor calcification (P = .47), post-operative epilepsy (P = .26), 
intraaxial growth (P = .37), or post-operative hematocrit levels (P = .40) (Supplementary Table 
6). Group A was associated with inferior cardiovascular outcome in most subgroups, but not in 
male patients, patients with multiple meningiomas or patients with posterior fossa meningiomas 
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(Supplementary Figure 3). Among embolized patients, a time to surgery of one week or less 
versus longer intervals were not associated with cardiovascular outcome (OR 0.61, 95% CI 0.23-
1.63, p=0.32), and applying receiver operator characteristics (ROC) curve analyses to 
cardiovascular outcome identified no predictive cut-off for the time interval between 
embolization and surgery (sensitivity 58%, specificity 46%, Supplementary Figure 2B). 
Similar analyses evaluating risk factors for adverse neurological outcome 3 months after surgery 
were also performed and similarly identified associations with embolization (OR 1.85, 95% CI 
1.30-2.63, P = .001), whereas radiographic gross total resection was associated with better 
neurological outcome (OR 0.59, 95% CI 0.39-0.87, P = .006), with no significant interaction 
between both predictors (P = .17). Further details are summarized in Supplementary Tables 7 and 
8, and Supplementary Figure 3. 
 
 
Recurrence-free survival by embolization status 
 
Tumor recurrence during the entire follow-up period was documented in 167 patients, including 
87 of 337 patients (25.8%) in group A and 80 of 404 patients (19.8%) in group B (P = .052). The 
median recurrence-free survival (RFS) was 12 years in patients with embolization and not 
reached in patients without embolization (P = .043). Multivariate analyses applying a Cox 
proportional hazards model of shorter RFS that controlled for the established prognostic factors 
outlined in Table 3 rendered WHO grade II or grade III versus grade I the strongest factor 
associated with shorter RFS (HR 3.83, 95% CI 2.30-6.37, P < .001). Therefore, we also 
performed analyses segregated by WHO grade.  
The RFS in group A versus group B did not differ in patients with WHO grade I meningiomas (P 
= .89, Figure 2A). Among patients with WHO grade II or grade III meningiomas, the RFS was 
4.3 years in group A versus 7.0 years in group B (P = .029, Figure 2B) and outcome with respect 
to RFS was less favorable in group A versus group B in a similar Cox model (HR 1.92, 95% CI 
0.97-3.79, P = .062). 
Molecular tumor characteristics may predict the clinical course more accurately than histology 
alone, and such approaches to re-classify meningiomas include genome-wide methylation 
signatures that are more closely associated with recurrence than histological WHO grading [15]. 
Gene methylation-based classification of prognostic molecular subtypes was available from 81 
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patients, including 41 patients assigned to the benign subtype and 40 patients with an 
intermediate (N=35) or malignant (N=5) gene methylation pattern. Paralleling the prognostic role 
of WHO grading, an intermediate or malignant versus benign gene methylation pattern was the 
strongest factor associated with shorter time to re-intervention when replacing WHO grade in the 
Cox model utilizing the variables outlined in Table 3 (HR 8.66, 95% CI 3.00-25.05, P < .001). 
The RFS in group A versus group B did not differ in patients with benign subtype meningiomas 
(P = .11, Figure 2C). Among patients with intermediate or malignant subtype meningiomas, the 
time to re-intervention was 2.0 years in group A versus 8.2 years in group B (P = .005, Figure 
2D) and outcome was less favorable in group A versus group B in a similar Cox model (HR 4.08, 
95% CI 0.91-18.21, P = .066).  
 
 
Discussion 
 
Here we have analyzed the post-operative outcomes of 741 consecutive patients with 
histologically diagnosed meningioma, including 337 patients that underwent pre-operative tumor 
embolization versus 404 patients who did not undergo embolization. Moreover, molecular 
meningioma subtypes with better prognostic accuracy compared to histological WHO grading 
[15] were defined by genome-wide methylation arrays in 81 patients. 
Outcome parameters after surgery included the likelihood of adverse cardiovascular events within 
3 months, persistence of neurological deficits with peri-operative new onset at 3 months and at 1 
year after surgery, and recurrence-free survival as defined by the time to re-intervention or tumor-
related death as a clinically relevant indicator. Multivariate analyses controlling for established 
prognosticators of outcome after meningioma surgery identified pre-operative embolization as an 
important risk factor for post-operative cardiovascular adverse events. Embolization was also 
associated with a higher rate of neurological adverse events after surgery, but no difference in the 
rate of neurological deficits 1 year after surgery. Recurrence-free survival was less favorable with 
embolization in patients with WHO grade II or grade III meningiomas, and with intermediate or 
malignant gene methylation patterns, but not in patients with WHO grade I or benign methylation 
subtype meningiomas. 
Prospective studies of the effects of embolization in meningioma patients are scarce [16] and 
mostly restricted to small series without comparator groups [5]. Previous reports of retrospective 
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cohorts focused on intraoperative blood loss, complication rates and comparison of these 
parameters with the use of different embolization materials [17-22]. Reports on associations of 
embolization with post-operative neurological outcomes are limited, with associations of 
embolization with cardiovascular adverse events or tumor recurrence not previously reported. To 
date, two recent studies explored associations of post-operative cardiovascular risk in 
meningioma patients [12,11]. In contrast to these studies, we did not detect associations of 
duration of surgery, older age and comorbidities with cardiovascular risk on multivariate 
analyses. Similar to previous reports, adverse neurological outcome was associated with 
cardiovascular risk and there was a previously not reported strong association of female gender. 
In our cohort, procedure-related complications from embolization occurred at low rates compared 
to previous studies [23], indicating a high level of experience of the interventional 
neuroradiologists. The use of PVA for embolization in all patients of our cohort and uniform 
standards of post-operative prophylaxis of thromboembolism [24] may have prevented 
confounding of the data by heterogeneous algorithms of care.  
Limitations of our study include the retrospective design and imbalances of key prognostic 
factors, albeit these were not prognostic on multivariate and subgroup analyses. The lack of an 
independent neuropathology review furthermore retains the possibility that the larger fraction of 
WHO grade II and grade III meningiomas among embolized patients were caused by 
misinterpretation of histological changes induced by the embolization procedure [7,8]. Yet, the 
shorter RFS with embolization among patients with WHO grade II or grade III meningiomas was 
confirmed utilizing an observer-independent molecular classification approach [15], which was 
more powerful in detecting survival differences than histological classification.  
Reasons for the shorter RFS with embolization are elusive, but the induction of mitotic activity 
that is commonly observed around necrotic tumor fractions after embolization may have 
contributed to accelerated tumor growth. Furthermore, larger tumor size and edema on pre-
operative imaging scans were associated with the decision to perform embolization. These 
indicators of less favorable disease courses and of more challenging surgery were reflected by a 
longer duration of surgery and have likely contributed to the higher rate of neurological deficits 
and shorter RFS in embolized patients, albeit embolization was identified as the most relevant 
prognostic factor on multivariate models of neurological outcome and RFS. Moreover, the extent 
of devascularization achieved, or changes on diffusion weighted images are additional factors 
that may have been associated with outcome, but such data were not available. Compared to 
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clinical practice in most centers, the rate of embolization in our cohort was relatively high, thus 
potentially limiting the generalizability of our results. The high rate of embolization results from 
Zurich being a referral center over many years and potentially a bias towards offering this 
intervention to patients rather frequently. There certainly was a belief in benefit from 
embolization because of reducing bleeding risk.  
The reasons for the higher rate of cardiovascular events remain elusive. In consideration of the 
lack of an association with the cardiovascular risk profile of patients or with hematological 
parameters, we speculate that systemic factors released from necrotic tissue after embolization 
may have contributed to higher rates of thromboembolism in patients undergoing meningioma 
embolization. However, other factors that have not been assessed may have confounded our 
analyses, including steroid use or immobilization time after surgery. 
In conclusion, the adverse outcomes with embolization reported here emphasize the necessity of 
randomized trials to determine when the benefit outweighs the risk of pre-operative meningioma 
embolization and which patients may potentially benefit. Future prospective studies should 
include standardized assessments of the extent of devascularization and other clinically relevant 
outcome parameters beyond estimated blood loss, such as health-related quality of life, disability 
scores and neurological functioning. 
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Figure legends 
 
Figure 1. Imaging and histopathological effects of meningioma embolization. A, MRI and 
angiography of the internal carotid artery before and after embolization of a parasagittal 
meningioma. Contrast enhancement was assessed on T1-weighted sequences. FLAIR, fluid 
attenuated inversion recovery. B, Histopathological stainings of (i) a non-embolized portion of a 
transitional meningioma (WHO grade I, hematoxylin and eosin stain [H&E]), (ii) embolization 
material (PVA particles 45-150 μm) in a meningioma feeder artery (H&E), (iii) embolization-
induced necrosis and micro-bleeds (H&E) and (iv) peri-necrotic proliferation, Ki-67 
immunohistochemistry stain. Scale bar: 100 μm. 
 
Figure 2. Recurrence-free survival in patients with pre-operative embolization (group A) versus 
without embolization (group B). A, WHO grade I (N=606); B WHO grade II (N=114) or grade III 
(N=21); C, benign (ben) gene methylation subtype (N=41); D, intermediate (N=36) or malignant 
(N=5) gene methylation subtype. The log rank test was applied to assess differences in time to re-
intervention. 
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Supplementary Figure 1. Study population. 
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Supplementary Figure 2. Timing of embolization. A, Frequency distribution of the 
time between embolization and surgery. B, ROC curve analysis of timing of 
embolization utilizing cardiovascular events as the outcome. 
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Supplementary Figure 3. Subgroup analyses. Indicated subgroups were analyzed 
for an association of pre-operative tumor embolization with inferior neurological 
outcome at 3 months after surgery or cardiovascular events within 3 months after 
surgery in the multivariate binary regression model outlined in Table 3. 
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Supplementary Table 1. Histological subtypes of patients with versus without 
embolizationa. 
 Embolization  
 Yes (group A)  
N=304 (48.3%) 
No (group B) 
N=325 (51.7%) 
 
P 
WHO grade I: N (%)    
Meningothelial 130 (42.8) 154 (47.4) .24 
Fibrous 33 (10.9) 34 (10.5) .87 
Transitional 49 (16.1) 58 (17.8) .56 
Psammomatous 3 (1.0) 11 (3.4) .042 
Angiomatous 7 (2.3) 10 (3.1) .55 
Microcystic 2 (0.7) 4 (1.2) .69* 
Secretory 9 (3.0) 6 (1.8) .44* 
Lymphoplasmacyte-rich - 2 (0.6) n.a. 
Metaplastic - 1 (0.3) n.a. 
WHO grade II: N (%)    
Atypical  53 (17.4) 36 (11.1) .022 
Clear cell  1 (0.3) - n.a. 
Chordoid 1 (0.3) 4 (1.2) .37* 
WHO grade III: N (%)    
Rhabdoid 1 (0.3) - n.a. 
Papillary 2 (0.7) - n.a. 
Anaplastic 13 (4.3) 5 (1.5) .054* 
 
a N=629 patients with detailed histopathologic reports available; * Fisher’s exact test, 
2-sided 
 
 
 
6 
Supplementary Table 2. Imaging characteristics of patients with versus without 
embolization. 
 Embolization  
 Yes (group A) 
N=332 (46.7%) 
No (group B) 
N=379 (53.3%) 
P 
Calcification: N (%)    
  Yes 
  No 
74 (22.3) 
258 (77.7) 
122 (32.2) 
257 (67.8) 
.003 
Hyperostosis: N (%)    
  Yes 
  No 
102 (30.7) 
230 (69.3) 
99 (26.1) 
280 (73.9) 
.17 
Intraosseus growth: N 
(%) 
  
 
  Yes 
  No 
19 (5.7) 
313 (94.3) 
15 (4.0) 
364 (96.0) 
.27 
Extracranial growth: 
N (%) 
  
 
  Yes 
  No 
24 (7.2) 
308 (92.8) 
19 (5.0) 
360 (95.0) 
.22 
Intraaxial growth: N 
(%) 
  
 
  Yes 
  No 
31 (9.3) 
301 (90.7) 
21 (5.5) 
358 (94.5) 
.052 
Infiltration of venous 
sinus: N (%) 
  
 
  Yes 
  No 
39 (11.7) 
293 (88.2) 
34 (9.0) 
345 (91.0) 
.22 
Radiographic EORa: 
N (%) 
  
 
  Gross total resection 
  Incomplete resection 
221 (69.1) 
99 (30.9) 
298 (80.3) 
73 (19.7) 
.001 
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Post-operative 
edemab: N (%) 
  
 
  Yes 
  No 
149 (45.0) 
182 (55.0) 
127 (34.8) 
238 (65.2) 
.006 
 
a EOR = extent of resection; documentation available in N=691 patients; b 
documentation available in N=696 patients 
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Supplementary Table 3. Adverse neurological and cardiovascular events 3 
months after meningioma resection in patients with versus without pre-operative 
embolization. 
 Embolization  
 Yes (group A) 
 N=337 (42.3%) 
No (group B) 
N=404 (57.7%) 
 
P 
Neurological eventsa    
Cranial nerve palsy: N (%)    
  Yes 
  No 
47 (13.9) 
290 (86.1) 
31 (7.7) 
373 (92.3) 
.006 
Trigeminal neuralgia: N (%)    
  Yes 
  No 
5 (1.5) 
332 (98.5) 
4 (1.0) 
400 (99.0) 
.54 
Sensorimotor deficit: N (%)    
  Yes 
  No 
51 (15.1) 
286 (84.9) 
51 (12.6) 
353 (87.4) 
.32 
Visual deficit: N (%)    
  Yes 
  No 
27 (8.0) 
310 (92.0) 
32 (7.9) 
372 (92.1) 
.96 
Epilepsy: N (%)    
  Post-operative new onset 
epilepsyb 
  Seizures within 1 week from 
surgery 
52 (23.7) 
 
20 (5.9) 
48 (16.8) 
 
25 (6.2) 
.052 
 
.89 
Neurocognitive deficits: N (%)    
  Yes 
  No 
29 (8.6) 
308 (91.4) 
38 (9.4) 
366 (90.6) 
.71 
CNS infection: N (%)    
  Yes 
  No 
7 (2.1) 
330 (97.9) 
6 (1.5) 
398 (98.5) 
.54 
Hydrocephalus: N (%)    
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  Yes 
  No 
17 (5.0) 
320 (95.0) 
9 (2.2) 
395 (97.8) 
.038 
Hemorrhage: N (%)    
  Yes 
  No 
109 (32.3) 
228 (67.7) 
97 (24.0) 
307 (76.0) 
.012 
  Clinically symptomatic    
   Yes 
   No   
57 (16.9) 
280 (83.1) 
32 (7.9) 
372 (92.1) 
< .001 
Re-craniotomy: N (%)    
  Yes 
  No 
20 (5.9) 
317 (94.1) 
15 (3.7) 
389 (96.3) 
.16 
Cardiovascular events    
Ischemic stroke: N (%)    
  Yes 16 (4.7) 13 (3.2) 
.29 
  No 321 (95.3) 391 (96.8) 
Myocardial infarction: N (%)    
  Yes 0 (0.0) 2 (0.5) 
.50* 
  No 337 (100.0) 402 (99.5) 
Sinus vein thrombosis: N (%)    
  Yes 5 (1.5) 5 (1.2) 
1.000* 
  No 332 (98.5) 399 (98.8) 
Deep vein thrombosis: N (%)    
  Yes 24 (7.1) 15 (3.7) 
.039 
  No 313 (92.9) 389 (96.3) 
Pulmonary embolism: N (%)    
  Yes 42 (12.5) 22 (5.4) 
.001 
  No 295 (87.5) 382 (94.6) 
Deathc    
  Yes 5 (1.5) 1 (0.2) 
.098* 
  No 332 (98.5) 403 (99.8) 
 
a not including worsening of pre-existing neurological symptoms. b N=505 patients 
without pre-operative epilepsy. c including death from cardiovascular complications 
and sudden unexplained death. * Fisher’s exact test, 2-sided 
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Supplementary Table 4. Post-operative hematological parameters of patients 
with versus without pre-operative embolization. 
  Embolization  
 Yes (group A)  
N=336 (47.4%) 
No (group B) 
N=373 (52.6%) 
P 
International normalized ratio    
  Median 1.0 1.0 
.054 
  Range 0.8-1.3 0.8-1.4 
Thrombin timea: seconds    
  Median 14 14 
.90 
  Range 10-200 10-56 
Activated prothrombin timeb: 
seconds 
   
  Median 25 26 
.092 
  Range 17-61 19-59 
Partial thromboplastin timec: 
seconds 
   
  Median 24 23 
.57 
  Range 18-35 15-47 
Fibrinogend: grams per liter    
  Median 3 3 
.50 
  Range 2-8 1-7 
Thrombocytes: N per nanoliter    
  Median 203 220 
.002 
  Range 59-526 55-705 
Hematocrit: %    
  Median 30.9 32.3 
< .001 
  Range 21.0-44.8 20.1-46.4 
 
a Data available in N=231 patients; b Data available in N=238 patients; c Data 
available in N=456 patients; d Data available in N=306 patients 
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Supplementary Table 5. Univariate analyses of variables tested in the 
multivariate models outlined in Table 3. 
 Cardiovascular events 
Variable Odds ratio and 95% CI P 
Group A versus group B 2.38 (1.52-3.70) < .001 
Demographics   
- Age: 18-54 versus 55+ 0.68 (0.43-1.06) .091 
- Gender: female versus male 2.56 (1.45-4.55) .001 
WHO grade: I versus II/III  1.12 (0.65-1.95) .69 
Imaging characteristics   
- Max diameter: 40+ versus <40 1.39 (0.87-2.21) .17 
- Multiple meningiomas: yes versus no 1.01 (0.55-1.86) .97 
- Radiographic extent of resection:  
  gross total versus incomplete 
0.82 (0.50-1.35) .44 
Cardiovascular risk factors: 0-1 versus 2+ 0.71 (0.45-1.11) .13 
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Supplementary Table 6. Additional single variables tested in the multivariate 
model outlined in Table 3. 
 Cardiovascular events 
Variable  Odds ratio and 95% 
CI 
P 
Edema: 
- before surgery 
- after surgery  
 
1.02 (0.63-1.66) 
0.89 (0.55-1.44) 
 
.93 
.64 
Duration of surgery: > 4h versus >4h 1.31 (0.78-2.19) .31 
Tumor location skull base: yes versus no 2.33 (1.40-3.86) .001 
Tumor location parasagittal: yes versus no 0.44 (0.20-0.98) .045 
Tumor location convexity: yes versus no 0.78 (0.38-1.47) .41 
Tumor location posterior fossa: yes versus no 0.63 (0.26-1.54) .32 
Calcification: yes versus no 0.83 (0.51-1.37) .47 
Post-operative epilepsy: yes versus no 1.33 (0.81-2.22) .26 
Pre-operative neurological deficit: yes versus no 1.20 (0.76-1.92) .43 
Intra-axial growth: yes versus no  1.49 (0.62-3.62) .37 
Adverse neurological outcome: yes versus no 1.75 (1.05-2.86) .032 
Thrombocytes per nl: 250+ versus < 250 0.55 (0.29-1.05) .069 
Hematocrit: 0.32+ versus < 0.32 0.81 (0.49-1.34) .40 
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Supplementary Table 7. Multivariate analyses of predictors for adverse 
neurological outcome 3 months after meningioma resectiona. 
 Adverse neurological outcome 
 
 Univariate analyses Multivariate analyses 
 OR (95% CI) P OR (95% CI) P 
Group A versus group B 1.64  
(1.22-2.17) 
.001 
1.85  
(1.30-2.63) 
.001 
Demographics     
- Age: 18-54 versus 55+ 1.31  
(0.98-1.75) 
.069 
1.16  
(0.83-1.61) 
.38 
- Gender:  
  female versus male 
0.75  
(0.55-1.02) 
.064 
0.79  
(0.59-1.13) 
.20 
WHO grade: I versus II/III  0.70  
(0.48-1.01) 
.059 
0.86  
(0.55-1.34) 
.49 
Imaging characteristics     
- Max diameter:  
  40+ versus <40 
1.06  
(0.77-1.45) 
.72 
1.23  
(0.86-1.75) 
.26 
- Multiple meningiomas:  
  yes versus no 
1.59  
(1.05-2.38) 
.026 
1.55  
(0.96-2.48) 
.072 
- Radiographic extent of  
  resection: gross total  
  versus incomplete 
0.54  
(0.38-0.76) 
.001 
0.59  
(0.39-0.87) 
.009 
 
a N=612 patients with complete datasets were included 
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Supplementary Table 8. Additional single variables tested in the multivariate 
model outlined in Supplementary Table 7. 
 Adverse neurological outcome 
Variable  OR (95% CI) P 
Edema: 
- before surgery 
- after surgery  
 
0.97 (0.68-1.38) 
1.30 (0.92-1.82) 
 
.85 
.14 
Tumor location skull base: yes versus no 1.29 (0.90-1.87) .17 
Tumor location parasagittal: yes versus no 0.72 (0.47-1.12) .15 
Tumor location convexity: yes versus no 1.02 (0.68-1.56) .91 
Tumor location posterior fossa: yes versus no 0.84 (0.50-1.85) .54 
Calcification: yes versus no 0.78 (0.54-1.14) .19 
Post-operative epilepsy: yes versus no 1.08 (0.72-1.61) .72 
Pre-operative neurological deficit: yes versus no 1.18 (0.83-1.67) .36 
Intra-axial growth: yes versus no  1.56 (0.78-3.13) .21 
 
 
 
Table 1. Clinical characteristics of meningioma patients with versus without pre-
operative tumor embolization.  
 Embolization  
 Yes (group A) 
 N=337  
(42.3%) 
No (group B) 
N=404 
(57.7%) 
 
P 
Age at diagnosis: years    
  Median (years) 
  Range (years) 
57 
19-88 
59 
18-87 
.99 
Gender: N (%)    
  Male 
  Female 
103 (30.6) 
234 (69.4) 
130 (32.2) 
274 (67.8) 
.64 
WHO grade: N (%)    
  I 
  II 
  III 
258 (76.6) 
63 (18.7) 
16 (4.7) 
348 (86.1) 
51 (12.6) 
5 (1.2) 
.001 
Locationa: N (%) 288 334  
  Convexity 
  Parasagittal 
  Skull base 
  Posterior fossa 
  Other 
64 (19.0) 
64 (19.0) 
123 (36.6) 
36 (10.7) 
4 (1.2) 
94 (23.3) 
58 (14.4) 
126 (31.2) 
41 (10.1) 
16 (4.0) 
016 
.087 
.12 
.80 
.023 
Multiple meningiomas: N (%)    
  Yes 
  No 
46 (13.4) 
291 (86.6) 
69 (17.1) 
335 (82.9) 
.17 
Maximal diameter: mm    
at embolizationb: mm    
  Median 
  Range 
46 
8-107  
n.a. 
.51g 
at surgeryc: mm    
  Median 
  Range 
47 
23-90 
31 
10-96 
< .001 
Edema: N (%)    
at embolizationd:     
  Yes 
  No 
169 (78.6) 
46 (21.4) 
n.a. < .001g 
at surgerye:     
  Yes 
  No 
194 (60.1) 
129 (39.9) 
147 (43.2) 
193 (56.8) 
< .001 
Duration of surgeryf: Minutes    
  Median 
  Range 
270 
40-810 
210 
40-755 
< .001 
Simpson gradeg: N (%)    
  1 
  2 
  3 
  4 
  5 
52 (24.8) 
103 (49.0) 
18 (8.6) 
28 (13.3) 
9 (4.3) 
84 (35.7) 
107 (45.5) 
19 (8.1) 
24 (10.2) 
1 (0.4) 
.011 
Tumor recurrence during follow-
up: N (%) 
   
  Yes 
  No 
87 (25.8) 
250 (74.2) 
80 (19.8) 
324 (80.2) 
.051 
 
a N=626, not including patients with multiple meningiomas, b documentation 
available in N=215 patients , c documentation available in N=638 patients, d 
documentation of edema before embolization and before surgery available for 
comparison in N=215 patients, e  documentation available in N=663 patients, f 
documentation available in N=445 patients, g documentation available in N=610 
patients, g comparison with values in the same patients at surgery 
 
Table 2. Cardiovascular risk profile of patients with versus without pre-
operative embolization. 
 Embolization  
 Yes (group A) 
 N=327  
(45.5%) 
No (group B) 
N=404 
(54.5%) 
 
P 
Number of cardiovascular 
risk factors 
   
  0-1 
  >1 
227 (67.4) 
110 (32.6) 
275 (68.1) 
129 (31.9) 
.84 
Cardiovascular risk factors: 
N (%) 
   
  Diabetes 
  Arterial hypertension 
  Dyslipidemia 
  Positive family history 
  Smoking 
  Body mass index >30 kg/m2 
31 (9.2) 29 (7.2) .32 
100 (29.7) 112 (27.7) .56 
24 (7.1) 35 (8.7) .44 
71 (21.1) 95 (23.5) .43 
79 (23.4) 102 (25.2) .57 
78 (23.1) 79 (19.6) .23 
Pre-operative 
cardiovascular events: N (%) 
   
  Yes 
  No 
24 (7.1) 
313 (92.9) 
29 (7.2) 
375 (92.8) 
.98 
  Myocardial infarction 
  Stroke 
  Sinus vein thrombosis 
  Pulmonary embolism 
  Deep vein thrombosis 
7 (2.1) 
8 (2.4) 
0 (0.0) 
6 (1.8) 
5 (1.5) 
7 (1.6) 
12 (2.7) 
0 (0.0) 
9 (2.0) 
9 (2.0) 
.56 
.83 
n.a. 
.86 
.62 
 
Table 3. Multivariate analyses of predictors for adverse cardiovascular outcome after 1 
meningioma resectiona. 2 
 Cardiovascular events 
Multivariate model Odds ratio and 95% CI P 
Group A versus group B 2.38 (1.37-4.00) .002 
Demographics   
- Age: 18-54 versus 55+ 0.76 (0.46-1.27) .29 
- Gender: female versus male 2.18 (1.17-4.08) .014 
WHO grade: I versus II/III  1.22 (0.61-2.43) .58 
Imaging characteristics   
- Max diameter: 40+ versus <40 1.05 (0.63-1.78) .84 
- Multiple meningiomas: yes versus no 1.11 (0.56-2.19) .77 
- Radiographic extent of resection:  
  gross total versus incomplete 
0.84 (0.48-1.47) .34 
Cardiovascular risk factors: 0-1 versus 2+ 0.68 (0.41-1.13) .14 
 3 
a N=612 patients with complete datasets were included 4 
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